Study of new therapy for stomach cancer before surgery or for advanced disease
Part of Cancer, Digestive system clinical trials.
This study tests a combination of chemotherapy, immunotherapy, and a targeted drug called fruquintinib for people with stomach cancer. It is for two groups: those who can have surgery after treatment (neoadjuvant therapy) and those whose cancer is advanced or spread to limited areas (conversion therapy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed adenocarcinoma of the stomach or the junction between the stomach and esophagus.
- For the neoadjuvant group: your cancer is locally advanced (stage II, III, or IVA) and can be surgically removed; you have not had any prior cancer treatment.
- For the conversion therapy group: your cancer is locally advanced or has spread to limited areas (like certain lymph nodes, liver, lung, or peritoneum) but not to distant organs like brain or bone; your cancer is not HER2-positive.
- You are in good physical condition (ECOG score 0 or 1), meaning you can do most daily activities independently.
- You have not had a severe allergic reaction to any of the drugs used in this study (anti-angiogenesis drugs, monoclonal antibodies, or chemotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.